• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

60
4
3
3
1

COUNTRY

3
1

PRICE

14
16
20
71

PUBLISHED

0
4
6
71

PRODUCT TYPE

70
1

Prostate Cancer

The second leading cause of new cancer cases in men worldwide with over two million sufferers in the US alone, prostate cancer is typically a disease that affects older men and is thus on the increase as global life expectancies continue to rise. It is also one of the largest sectors of the pharmaceutical oncology industry. Expertly formulated reports in this section will help you to formulate effective market strategies by answering key questions such as who are the main and key niche players, what are the new drugs and therapies (including vaccines and therapeutic antibodies) in the pipeline, and what are the latest areas of pharmaceutical R&D. Manufacturers will find multiple report options to assist them in assessing competition and market opportunities. Show Less Read more

PRODUCT TITLE
Prostate Cancer Pipeline Highlights - 2015 Prostate Cancer Pipeline Highlights - 2015 - Product Thumbnail Image

Prostate Cancer Pipeline Highlights - 2015

The latest report Prostate Cancer Pipeline Highlights – 2015, provides most up-to-date information on key pipeline molecules in the global Prostate Cancer market. It covers emerging therapies for Prostate...

November 2014
FROM

Global Prostate Cancer Drugs Market 2014-2018

About Prostate Cancer Prostate cancer initiates in the prostate, which is an exocrine gland present in the male reproductive system. The main function of the prostate is to make fluid for semen. The...

November 2014
FROM
Prostate Cancer Drug Pathway Analyzer 2014 Prostate Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Prostate Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 403 targeted molecular therapies known to affect more than 247 specific intracellular signaling pathways...

November 2014
FROM
Prostate Cancer Drug Pipeline Update 2014 Prostate Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Prostate Cancer Drug Pipeline Update 2014

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various...

October 2014
FROM

Prostate Cancer Treatment Drugs Markets in China

China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

June 2014
FROM
Analytical Tool - Prostate Cancer Analytical Tool - Prostate Cancer - Product Thumbnail Image

Analytical Tool - Prostate Cancer

"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same...

March 2014

US Prostate Cancer Drug Pipeline Analysis

Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the...

October 2013
FROM
Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Antibodies Triple Analysis: Melanoma, Prostate Cancer and Antibodies - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Melanoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Apoptosis Triple Analysis: Melanoma, Prostate Cancer and Apoptosis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Prostate Cancer Triple Analysis: Leukemia, Melanoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM

KOL Insight: Prostate Cancer: Competition Intensifies in Race to the Top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

June 2013
FROM
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top - Product Thumbnail Image

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new...

June 2013
FROM
Triple Analysis: Prostate Cancer, Apoptosis and Peptides Triple Analysis: Prostate Cancer, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Prostate Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies - Product Thumbnail Image

Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound...

November 2012
FROM
Triple Analysis: Pancreatic Cancer, Prostate Cancer and Antibodies Triple Analysis: Pancreatic Cancer, Prostate Cancer and Antibodies - Product Thumbnail Image

Triple Analysis: Pancreatic Cancer, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

November 2012
FROM
Loading Indicator

Our Clients

Our clients' logos